Ads
related to: new blood thinner medication pradaxa side effects
Search results
Results From The WOW.Com Content Network
Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. [6] [7] Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. [6]
Prior to the introduction of direct factor Xa inhibitors, vitamin K antagonists such as warfarin were the only oral anticoagulants for over 60 years, and together with heparin have been the main blood thinners in use. People admitted to hospital requiring blood thinning were started on an infusion of heparin infusion, which thinned blood ...
Hence, blood-thinning medications can be prescribed to reduce the risk of cardiovascular diseases led by blood clots, such as myocardial infarction (heart attack), ischemic stroke, and venous thromboembolism. [35] Haemorrhage (internal bleeding) is the most prominent side effect of blood-thinning therapy. [36]
Replacing the 50 year old Warfin blood thinner with new next generation solutions is setting 2014 up as an important year for Bayer and Johnson & Johnson . Those two companies co-market fast ...
It had hoped the drug would generate annual sales of more than 5 billion euros ($5.5 billion) and replace revenue from one of its pharmaceutical best-sellers, blood thinner Xarelto, which is set ...
Bayer executive Sebastian Guth told Reuters last March that the drugmaker intended to move away from relying on partners in the U.S. and planned to spend $1 billion on drug research and ...
Common side effects include pneumonia and urinary tract infections. [9] Severe side effects may include blood clots or cardiac arrest. [9] Andexanet alfa has a boxed warning that it is associated with arterial and venous blood clots, ischemic events, cardiac arrest, and sudden deaths. [8]
Researchers are working to develop a unique anticoagulant (blood thinner) that would bring a lower risk of bleeding than the options currently on the market.